Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Iveric Bio Inc
(NQ:
ISEE
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 10, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Iveric Bio Inc
< Previous
1
2
3
4
Next >
IVERIC bio Inc. (NASDAQ: ISEE) Records 52-Week High Thursday Morning
July 06, 2023
Via
Investor Brand Network
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023
From
IVERIC bio, Inc.
Via
Business Wire
IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE
June 14, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
IVERIC bio Inc. (NASDAQ: ISEE) Making Surprising Moves in Monday Session
June 05, 2023
Via
Investor Brand Network
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
June 01, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2023
From
IVERIC bio, Inc.
Via
Business Wire
IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE
May 02, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Iveric Bio Inc. (Nasdaq – ISEE), Midwest Holding Inc. (Nasdaq – MDWT), Hoth Therapeutics, Inc. (Nasdaq – HOTH)
May 01, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
ISEE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Iveric bio, Inc. Is Fair to Shareholders
May 01, 2023
From
Halper Sadeh LLC
Via
Business Wire
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
April 30, 2023
From
IVERIC Bio, Inc.
Via
Business Wire
Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting
April 23, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results
March 01, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials
March 01, 2023
From
Iveric Bio
Via
Business Wire
Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023
February 22, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy
February 16, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors
January 03, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy
December 20, 2022
From
Iveric bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock
November 30, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces Proposed Offering of Common Stock
November 30, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy
November 17, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Present at Upcoming Investor Conferences
November 04, 2022
From
Iveric Bio
Via
Business Wire
Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy
November 03, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results
November 03, 2022
From
IVERIC bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.